GLOBAL DERMATOLOGY ESSENTIALS: Psoriasis

Event Starts:

You must be registered on the site and logged in to register for the Event

This GD Essentials focuses on psoriasis, a chronic inflammatory dermatosis that affects millions of people worldwide. This event aims to bring together experts and researchers in the field of dermatology to discuss the latest advancements and research on psoriasis. It is chaired by Professor Alexander Navarini (Swizerland) and moderated by Dr. Mendrika Fifaliana RAKOTOARISAONA.

Psoriasis is a challenging condition that significantly impacts patients’ quality of life. Over the years, traditional treatments have evolved to target specific inflammatory loops involved in psoriasis, such as anti-TNFalpha, anti-IL-17, IL-23, and small molecules like Aprémilast. The development of small molecules has opened new possibilities for effective and convenient treatment options.

During this event, renowned speakers and experts will present their insights on various aspects of psoriasis. The presentations will cover a wide range of topics, including general pustular psoriasis, current guidelines, and future treatments. Additionally, the event will focus on the role of teledermatology in the diagnosis and therapy of psoriasis, as well as the cardiovascular comorbidities associated with the condition.

Prof. Ahmed Samaouel CHEHAD MD from Algeria provides an introduction to psoriasis and the importance of small molecules in its treatment.

Prof. Adam REICH MD, PhD from Poland discusses the current guidelines and future treatments for general pustular psoriasis, shedding light on the promising role of anti-Interleukin-36 (IL-36) therapy.

Prof. Alexander NAVARINI MD, PhD from Switzerland shares valuable insights into the use of teledermatology in the diagnosis and therapy of psoriasis, highlighting its benefits in improving access to care.

Prof. Tiago TORRES MD, PhD from Portugal delves into the relationship between psoriasis and cardiovascular comorbidities, exploring the potential of biological therapy in managing both skin symptoms and cardiovascular risk factors.

Gain a comprehensive understanding of psoriasis and its treatment options, focusing on the role of small molecules and other innovative approaches. The event offers a unique opportunity for researchers, dermatologists, and healthcare professionals to exchange knowledge, discuss advancements, and foster collaborations in the field of psoriasis.

About the Organizers:

This Essentials symposium is curated by the organizers of the World Skin Health Day | Guinea 2024. Introduced by the World Health Organization under the auspices of the International Society of Dermatology, the World Skin Health Day | Guinea 2023 hosted over 100 high-profile presentations accredited with 30 UEMS-EACCME® credits.

Essentials are hosted on Global Dermatology. Initiated in 2009, Global Dermatology empowers Dermatologists to engage with evidence-based resources, explore clinical cases, and deepen medical knowledge, right at the point of care. The GD Inquire^TM App. provides a unique inquiry-based learning approach in skin health.

General pustular psoriasis: current guidelines and future treatments

Based on current understanding, the diagnosis of general pustular psoriasis (GPP) requires observation of primary, sterile, macroscopically visible pustules on non-acral skin, and it must be a relapsing disease, with symptoms lasting more than three months or recurring episodes. Anti-Interleukin-36 (IL-36) therapy shows promise in treating GPP, as research suggests that deficiency of the antagonist of the IL-36 receptor is linked to the disease’s pathogenesis. However, more research is needed to fully understand the role of IL-36 in GPP and its potential as a therapeutic target. Until then, the management of GPP should follow current guidelines, including systemic treatment and supportive care to control symptoms and prevent complications.

Prof. Alexander Navarini MD. PhD (Switzerland)

Alexander Navarini is a clinician-scientist physician based in Basel, Switzerland. He is a quantitative dermatologist, experimental immunologist and trained in modern genetics.

Born in Basel, raised in Kantons GR and AG, medical studies in Basel and Paris. Training as MD PhD experimental immunologist in Zurich. Residency in internal medicine at Bruderholzspital, tropical medicine at Swiss Tropical Institute, and dermatology at University Hospital Zurich. Senior resident research fellowship in modern genomics at King’s College London. Was attending physician and deputy head of outpatient clinic at Department of Dermatology, University Hospital Zurich. Since November 2018 Chair of Dermatology at the University Hospital of Basel

Psoriasis in-person consultations and teledermatology – diagnosis and therapy

Teledermatology is a valuable tool in dermatology that allows healthcare providers to remotely diagnose and treat skin conditions. It is particularly useful for patients with psoriasis, as it enables them to receive timely and convenient care without having to visit a physical clinic. With reproducible algorithms and good standard quality, Teledermatology can provide accurate diagnoses and prescribe appropriate treatments. Store-and-forward Teledermatology is commonly used, where the patient takes photos of their skin problem and sends them to the dermatologist for diagnosis and treatment. Video conferencing is another option. Overall, Teledermatology is a promising technology that can improve access to care for patients with psoriasis.

Prof. Tiago Torres Md. PhD

Cardiovascular comorbidities and Psoriasis

Psoriasis patients commonly experience cardiometabolic comorbidities, including obesity, hypertension, dyslipidemia, diabetes, and metabolic syndrome, which increase their risk of cardiovascular disease. Psoriasis-associated inflammation contributes to atherosclerosis, exacerbated by the comorbidities. Obesity is a central risk factor in psoriasis due to its role in inflammation and adipose tissue dysfunction. Epicardial adipose tissue volume increases in psoriasis, further contributing to cardiovascular risk. However, biological therapy targeting inflammatory cytokines and adipokines involved in psoriasis and cardiovascular disease has shown promise in reducing inflammation, psoriasis symptoms, and cardiovascular risk factors. Integrating biological therapy in psoriasis management can improve skin symptoms and reduce cardiovascular risk.